ClinicalTrials.gg
CompletedNCT06355479Updated Apr 9, 2024

A Study to Evaluate the Efficacy and Safety of OsrHSA in Patients of Hepatic Cirrhosis With Hypoalbuminemia

A Phase 3 interventional study of OsrHSA and Plasbumin®-20 in Hypoalbuminemia and Hepatic Cirrhosis, sponsored by Healthgen Biotechnology Corp.. Completed at 37 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-09.

Sponsored by Healthgen Biotechnology Corp. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.
  • Registered 11 months after the study started (first participant enrolled Apr 2023, registered Mar 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the efficacy of OsrHSA works to treat hypoalbuminemia in hepatic cirrhosis patients. It will also learn about the safety and immunogenicity of OsrHSA. The main question it aims to answer is whether OsrHSA is effective in elevating the serum albumin level of cirrhotic patients with hypoalbuminemia.

Researchers will compare OsrHSA to the positive comparator, plasma-derived HSA (pHSA) to see if OsrHSA presents as non-inferior to pHSA in the indication of hypoalbuminemia in hepatic cirrhosis patients.

Participants will be randomized in a 1:1 ratio to receive OsrHSA or HpHSA (20g IV qd) for up to 14 days, following an EOT visit. Follow-up visits will be taken on EOT+7d, EOT+14d, and EOT+30d, respectively.

02

Conditions studied

  • Hypoalbuminemia
  • Hepatic Cirrhosis
03

In context

Hypoalbuminemia

41 studies on the registry are indexed under Hypoalbuminemia; 9 are open to participants now.

This study's enrollment of 328 is above the median of 70 across 25 interventional studies indexed under Hypoalbuminemia.

Browse Hypoalbuminemia studies →

Lead sponsor

Healthgen Biotechnology Corp. is the lead sponsor of 8 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  1. Diagnosis of hepatic cirrhosis
  2. Adult males or females, aged 18-75 years (both inclusive) at the time of consent
  3. Serum albumin level ≤ 30 g/L
  4. Capable of giving , which includes compliance with the requirements and restrictions listed in the informed consent form and this protocol

Main Exclusion Criteria:

  1. History of allergy to rice; a history of allergy to any component of the HpHSA product
  2. Therapeutic/ Large-volume paracentesis (> 5L each time) during the treatment period
  3. Ascites resulted from non-hepatic cirrhosis, Budd-Chiari syndrome
  4. Participants with Grade III or Grade IV hepatic encephalopathy using West Heaven Criteria
  5. A transjugular intrahepatic peritoneal shunt (TIPS) is performed within 1 month prior to the first dosing
  6. Evidence of upper gastrointestinal hemorrhage 6 months prior to the first dosing
  7. Participants with stage C and stage D hepatocellular carcinoma according to China Liver Cancer Staging (CNLC) Classification
  8. Evidence of extrahepatic neoplastic disorders
  9. Transplantation
  10. positive
  11. Participants with pleural effusion and need therapeutic thoracentesis during the treatment period
  12. Uncontrolled infection with body temperature ≥ 38.5 degrees Celsius (101.3 degrees Fahrenheit) or ≤ 35 degrees Celsius (95 degrees Fahrenheit) and white blood cells > 12.0×10\^9/L. i.e. severe intraabdominal infections, sepsis, respiratory tract infections, urine tract infections.
  13. Other serious underlying diseases, including but not limited to: hepatopulmonary syndrome, heart failure grade III-IV ( scale of heart function), severe structural heart disease, symptomatic ischemic heart disease, severe chest and lung disease, hemodialysis, active biliary obstructive disease, etc.
  14. With the following abnormal laboratory test values:

    Hematology: white blood cell count \< 2.0×10\^9/L, \< 1.0×10\^9/L, \< 30×10\^9/L, or \< 75 g/L; Chemistry: and/or AST > 5× (ULN), total > 3× ULN; Coagulation: >2.0; Renal function: Cr > 2×ULN, urine protein >2+; Echocardiography: \< 50%

  15. Pregnant or breastfeeding or plan to get pregnant in 6 months
  16. Potentially fertile participants (other than women who have undergone hysterectomy, bilateral salpingectomy, bilateral tubal ligation, or for more than 1 year, and men who have undergone bilateral vasectomy) who do not consent to or are unable to use effective throughout the study and 120 days after the end of the study (or early discontinuation of the study);
  17. Enrolled in any clinical trials within 3 months prior to the first dose of study intervention
  18. Any other condition that the investigator considers would make the participant unsuitable for the clinical trial
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    OsrHSA

    OsrHSA 20g, IV qd, Day1 up to Day 14

    Drug: OsrHSA

  • Active comparator
    pHSA

    pHSA 20g, IV qd, Day1 up to Day 14

    Drug: Plasbumin®-20

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the efficacy of OsrHSA on elevating the serum albumin level.

    Percentage of participants whose albumin level reaches 35 g/L or above at any time up to 14 days of the study intervention.

    Time frame: Day 1 to Day 14

Secondary outcomes

  1. To estimate the time to reach 35 g/L or more in serum albumin

    Time to reach serum albumin 35 g/L or more by the end of the treatment (EOT)

    Time frame: Day 1 to Day 14

  2. To estimate the change from baseline in serum albumin

    To estimate the change from baseline to the end of treatment (EOT) in serum albumin

    Time frame: Day 1 to Day 14

  3. To estimate the change from baseline in colloid osmotic pressure

    The change from baseline to the end of treatment (EOT) will be measured in Colloid osmotic pressure

    Time frame: Day 1 to Day 14

  4. To estimate the change from baseline in body weight

    The change in body weight will be measured from baseline to the end of treatment (EOT)

    Time frame: Day 1 to Day 14

  5. To estimate the change from baseline in abdominal circumference, and ascites severity

    The change in abdominal circumferences will be measured from baseline to the end of treatment (EOT)

    Time frame: Day 1 to Day 14

  6. To estimate the change from baseline in ascites severity

    The change in ascites severity will be measured from baseline to the end of treatment (EOT)

    Time frame: Day 1 to Day 14

07

Study locations

37 sites
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing, China
  • Beijing Youan Hospital, Capital Medical University
    Beijing, Beijing, China
  • Chongqing University Three Gorges Hospital
    Chongqing, Chongqing, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • The First Affiliated Hospital of Fujian Medical University
    Fuzhou, Fujian, China
  • Nanfang Hospital
    Guangzhou, Guangdong, China
  • The Third Affiliated Hospital, Sun Yat-Sen University
    Guangzhou, Guangdong, China
  • Huizhou Central People's Hospital
    Huizhou, Guangdong, China
  • Affiliated Hospital of Guilin Medical University
    Guilin, Guangxi, China
  • Liuzhou Worker's Hospital
    Liuzhou, Guangxi, China
  • The First Affiliated Hospital of Guangxi Medical University
    Nanning, Guangxi, China
  • Affiliated Hospital Of Zunyi Medical University
    Zunyi, Guizhou, China
  • The Fourth Affiliated Hospital, Harbin Medical University
    Harbin, Heilongjiang, China
  • Luoyang Central Hospital
    Luoyang, Henan, China
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan, China
  • The Sixth People's Hospital of Zhengzhou
    Zhengzhou, Henan, China
  • Jingzhou Central Hospital
    Jingzhou, Hubei, China
  • TaiHe Hospital
    Shiyan, Hubei, China
  • The Central Hospital of Wuhan
    Wuhan, Hubei, China
  • Wuhan Jinyintan Hospital
    Wuhan, Hubei, China
  • Yichang Central People's Hospital
    Yichang, Hubei, China
  • Yueyang Central Hospital
    Yueyang, Hunan, China
  • The Third People's Hospital of Zhenjiang
    Zhenjiang, Jiangsu, China
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi, China
  • Pingxiang People's Hospital
    Pingxiang, Jiangxi, China
  • Yichun People's Hospital
    Yichun, Jiangxi, China
  • Hepatobiliary Hospital Of Jilin
    Chang chun, Jilin, China
  • The First Hospital of Jilin University
    Chang chun, Jilin, China
  • The Sixth People's Hospital of Shenyang
    Shenyang, Liaoning, China
  • The People's Hospital of Qinghai
    Xining, Qinghai, China
  • Shandong Public Health Clinical Center
    Jinan, Shandong, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan, China
  • Ruian People's Hospital
    Rui'an, Zhejiang, China
  • The First School of Medicine, School of Information and Engineering, The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Zhejiang, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Nov 2023, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2024
First posted
Apr 9, 2024
StartActual
Apr 10, 2023
Primary completionActual
Nov 22, 2023
CompletionActual
Dec 12, 2023
Last update
Apr 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06355479
Lead sponsor
Healthgen Biotechnology Corp.
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 10, 2023
Primary completion
Nov 22, 2023
Completion
Dec 12, 2023
Last update
Apr 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human serum albumin, recombinant rice-derived

Start the discussion